Holoclara Inc

Fierce Biotech highlighted the start of our clinical trials for HC002, a first-in-class worm-derived therapy. Read the article to learn more about our Phase 1 study and lead indication, eosinophilic esophagitis (EoE): https://lnkd.in/giVx9zTY Thanks to Darren Incorvaia for speaking with our co-founder and CEO Andrea Choe about our work to harness molecules identified in worms for breakthrough medicines, plan to expand to other critical indications, and more.

We’re pleased to announce our first-in-human Phase 1 clinical trial of HC002 – a novel worm-derived medicine – and eosinophilic esophagitis (EoE) as our lead indication. 💊 More on HC002 and our Phase 1 study: - An investigational, orally bioavailable small molecule therapy harnessing the therapeutic potential of worms to address historically untreatable diseases - Study testing the safety and tolerability of HC002 in healthy adults will be conducted in partnership with Novotech and CMAX Clinical Research 🩺 On EoE:  -  Chronic inflammatory disorder historically considered to be an orphan disease  - Rapid increase in prevalence to 1 in 700 people in the U.S. today makes it the second most common esophageal disease Check out the video and press releases below to learn more about our clinical progress from our CEO Andrea Choe, CMAX CEO Jane Kelly, principal investigator Thomas Polasek and Evan S. Dellon, leading gastroenterologist at the University of North Carolina at Chapel Hill School of Medicine. 🔗 Phase 1 press release (https://lnkd.in/g4ZMheam) and study details (https://lnkd.in/gwC6quXU) 🔗 Indication press release (https://lnkd.in/g6BF_tEs) #Worms #WormScience #WormTherapies #WormsAsMedicine #Allergies #Autoimmune #EosinophilicEsophagitis #Biotech #ClinicalTrials

In an interview with Pulse 2.0 editor in chief Amit Chowdhry, our co-founder and CEO Andrea Choe discusses our latest milestones, technology, and at the core of it all – our commitment to translating breakthrough science into solutions for patients. Give it a read 👉 https://lnkd.in/gdjb4Mtj #Worms #WormScience #WormTherapies #WormsAsMedicine #Allergies #Autoimmune #Biotech

📢 Holoclara has been selected as the winner of the Immunomodulatory Solution of the Year by the BioTech Breakthrough Awards! We’re proud to be developing first-in-class worm-derived therapies that could serve as breakthrough treatments for allergic and autoimmune disease. Read the full announcement 👉 https://lnkd.in/gYXC6PQ5 #WormScience #WormsAsMedicine #Worms #WormTherapies #Allergies #Autoimmune #Biotech

A scientist and a reporter walk into a worm lab. If this is a story you haven’t heard before, check out Allie Garfinkle’s recent feature in Fortune interviewing our co-founders, CEO Andrea Choe and advisor Paul Sternberg, and one of our investors, Neal Bhadkamkar at BOLD Capital Partners. They discuss worm behavior, their long evolutionary history with humans, and how it all led to our development of breakthrough worm-derived therapies. Bonus: Learn why some worms are called “dumpys” or “uncs.” 👉 https://lnkd.in/g-bQq4-g

The New York Times captures the incredible impact that #worms have made on science and medicine — including breakthroughs that have earned at least 4 Nobel Prizes. In honor of this year’s Nobel Prize in Chemistry, our team celebrates their ongoing contributions to biology as we harness worm-derived molecules to improve our health. For more on these “Worm Nobels,” read this delightful piece by Teddy Rosenbluth: https://lnkd.in/dKbmMFPs #WormScience #WormsAsMedicine #WormTherapies

What’s in a name? Our name Holoclara is derived from the Greek word 𝘩𝘰𝘭𝘰𝘬𝘭ē𝘳𝘰𝘴 meaning “complete.” 𝘏𝘰𝘭𝘰𝘬𝘭ē𝘳𝘰𝘴 reflects our mission to restore missing components of the human molecular legacy. To do so, we are harnessing worm-derived molecules into safe, orally available medicines.  Read more 👉 holoclara.com #WormScience #WormsAsMedicine #Worms #WormTherapies #Allergies #Autoimmune #Biotech

Did you know that autoimmune and allergic diseases were rare before the 1900s? What changed? 🤔🪱 Our co-founder and CEO Andrea Choe explores these questions on the latest episode of Life Sciences 360. Watch the full conversation with host Harsh Thakkar for more on how worms may be the key to tackling these diseases, and our work at Holoclara to develop worm-derived therapies. Watch the full episode: https://lnkd.in/gfBBKMHv #WormScience #WormsAsMedicine #Worms #WormTherapies #Allergies #Autoimmune #Biotech

Check out Forbes brand new science newsletter featuring our work harnessing worms for better human health! In the Prototype, Alex Knapp covers our co-founder and CEO Andrea Choe’s foundational discovery of worm-derived molecules that can suppress the inflammatory response in the immune system — and how our team is turning them into safe, orally available medicines that could benefit millions of patients. 👉https://lnkd.in/gFGxvm_c #WormScience #WormsAsMedicine #Worms #WormTherapies #Allergies #Autoimmune #Biotech

Thrilled to see our co-founder and advisor Paul Sternberg honored with this new appointment at Caltech!